Net profit rose 28% in the first three quarters

Fosun Pharmaceutical (600196) announced that the company's first three quarters to achieve business income of 3.329 billion yuan, an increase of 19% per cent, the realization of the net profit attributable to the parent company 738 million yuan, of which the operating net profit of 380 million yuan, excluding the dilution of the listed shares of the Chinese medicine, operating net profit growth of 28%　　To achieve 0.39 yuan per share income. The company said that the growth of operating net profit was mainly due to the continuous improvement of core pharmaceutical manufacturing and pharmaceutical commercial enterprises. In the first three quarters of this year, the company's core pharmaceutical companies pharmaceuticals, medicine, the new source of Hubei sales revenue have achieved rapid growth, growth of more than 25%.　　In the pharmaceutical business, the company's affiliated enterprises in the pharmaceutical industry continue to strengthen the status of the leading enterprises in drug distribution, the company's major pharmaceutical retail Enterprises forte Pharmacy, Golden Elephant Pharmacy and other continue to lead the region's pharmaceutical retail industry, the number of stores and profitability are living in the regional market leading position. At the same time, the company continued to increase the investment and integration of excellent enterprises in the industry. In the third quarter of this year, the company held the gene Chip diagnostics products Enterprise Asia Energy, increased the high-end medical services enterprises in the U.S.-China mutual benefit investment, but also invested in domestic well-known High-tech medical diagnosis Enterprise Dheere medical treatment. Recently, the company also plans to increase the size of the large pharmacy, the capital, after the completion of the company to the Golden Elephant pharmacy real rights and interests will be increased from 50% to 76.3%. Fosun said that the future will adhere to the "endogenous growth, extension expansion and integrated development" strategic thinking.